Saturday 17 October 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.04
0.15
−4.70%
Follow MNKD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 4 | 6 |
+8 more TTM periods Free account |
| 71.36% | 40.60% | (9.03%) | (22.97%) | ||
| (7.62%) | (4.14%) | 0.99% | 6.10% | ||
ROIC |
2.36% | 4.05% | 10.29% | 0.00% | |
Return on Tangible Assets |
(23.20%) | (12.01%) | 2.89% | 8.80% | |
Average Days of Receivables |
40.06 | 28.47 | 40.13 | 20.22 | |
Free Cash Flow per Share |
(0.06) | 0.04 | 0.04 | 0.14 | |
Free Cash Flow |
(18.13) | 13.15 | 13.69 | 43.39 | |
Capital Expenditures |
(10.08) | (6.12) | (4.57) | (5.47) | |
| Other line items | |||||
Cash ROIC |
(3.89%) | 2.65% | 2.37% | 10.12% | |
Accounts Receivable Turnover |
11.19 | 12.65 | 13.91 | 17.64 | |
Accounts Payable Turnover |
9.10 | 8.30 | 11.12 | 11.36 | |
Inventory Turnover |
2.66 | 2.25 | 2.78 | 2.90 | |
Average Days of Payables |
41.60 | 67.02 | 37.49 | 34.06 | |
Days of Inventory on Hand |
167.34 | 204.12 | 146.54 | 126.39 | |
Tax Rate |
(0.10) | (0.16) | 3.17 | (0.05) | |
Research and Development Expense of Revenue |
19.53% | 20.11% | 19.01% | 15.90% | |
Selling, General and Administrative Expense of Revenue |
50.78% | 48.01% | 41.30% | 34.96% | |
Share Based Compensation of Revenue |
7.11% | 7.00% | 6.93% | 6.73% | |
Interest Coverage |
0.19 | 0.37 | 1.02 | 2.31 | |
Operating CF/Net income |
0.18 | (0.81) | 3.11 | 1.67 | |
Depreciation/Fixed assets |
0.26 | 0.22 | 0.16 | 0.12 | |
Capex/Depreciation |
(0.45) | (0.34) | (0.35) | (0.56) | |
Revenue per Share |
1.27 | 1.17 | 1.14 | 1.02 | |
Operating CF per Share |
(0.03) | 0.06 | 0.06 | 0.16 | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.02) | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.02 |
Columns are period end dates